

# Distinguishing Frontotemporal Dementia From Alzheimer Disease Through Everyday Function Profiles: Trajectories of Change

Journal of Geriatric Psychiatry  
and Neurology

1-10

© The Author(s) 2020



Article reuse guidelines:

[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)

DOI: 10.1177/0891988720901791

[journals.sagepub.com/home/jgp](https://journals.sagepub.com/home/jgp)

Clarissa M. Giebel, PhD<sup>1,2</sup>, David Knopman, MD, PhD<sup>3</sup>,  
Eneida Mioshi, PhD<sup>4</sup>, and Mizanur Khondoker, PhD<sup>5</sup> 

## Abstract

**Background:** Different dementia syndromes display different patterns of everyday functioning. This article explored different patterns of functioning at baseline and trajectories of change in behavioral variant frontotemporal dementia (bvFTD) and Alzheimer disease (AD). **Methods:** Data from the Uniform Data Set of the National Alzheimer's Coordinating Centre were employed. The Functional Assessment Questionnaire assessed functioning at up to 7 follow-up visits. Independent *t* tests assessed variations in functioning between syndromes at baseline. Linear mixed-effect modeling explored longitudinal functional trajectories between syndromes. **Results:** Data from 3351 patients (306 bvFTD and 3,045AD) were analyzed. At baseline, patients with bvFTD performed all daily activities poorer than AD dementia. Linear mixed models showed a significant effect of syndrome and time on functioning, and evidence of interaction between syndrome and time, with bvFTD showing a steeper decline for using the stove and travel. **Conclusions:** Findings can help in the effective care planning of everyday functioning for bvFTD and AD dementia.

## Keywords

activities of daily living, Alzheimer disease, frontotemporal dementia

## Introduction

Increased dependency in everyday life is a hallmark of dementia.<sup>1</sup> Although deteriorations in basic and instrumental activities of daily living (bADLs/IADLs) are common in all dementia syndromes, some research indicates that everyday activities deteriorate differently across syndromes.<sup>2,3</sup>

Frontotemporal dementia (FTD) is characterized by heightened behavioral or semantic difficulties, language (semantic processing for primary progressive aphasia [svPPA] and motor speech for nonfluent variant of primary progressive aphasia [nfvPPA]), and motor functioning<sup>4-6</sup> and comprises a variety of syndromes, including behavioral variant frontotemporal dementia (bvFTD).<sup>7</sup> Some research suggests that patients with bvFTD experience greater levels of IADL impairments than patients with Alzheimer disease (AD) dementia,<sup>8</sup> with a recent study showing that directly observed performance of IADLs did not vary among syndromes, but initiative and planning were more impaired in bvFTD than in AD dementia based on indirect assessments.<sup>9</sup> However, there is some ambiguity in that Wicklund and colleagues<sup>10</sup> reported no significant variations among patients with AD dementia and bvFTD in activities of self-care, household, employment and recreation, shopping and money, and travel, but instead only in communication. In light of the limited

evidence comparing different dementia syndromes, there is a need to investigate these variations to help differentiate individual syndromes better from one another at the assessment stage.

Activities of daily living decline hierarchically, with specific activities such as dressing to deteriorate early on in the disease, while activities such as feeding deteriorate to a greater extent in the later stages.<sup>10-12</sup> However, IADL research has been more limited to date. Peres and colleagues<sup>13</sup> showed how finance management, telephoning, using transport, and managing medication were significantly impaired in a mixed sample

<sup>1</sup> Institute of Population Health Sciences, University of Liverpool, Liverpool, United Kingdom

<sup>2</sup> NIHR ARC NWC, Liverpool, United Kingdom

<sup>3</sup> Department of Neurology, Mayo Clinic, Rochester, MN, USA

<sup>4</sup> School of Health Sciences, University of East Anglia, Norwich, United Kingdom

<sup>5</sup> Norwich Medical School, University of East Anglia, Norwich, United Kingdom

Received 5/5/2019. Received revised 12/11/2019. Accepted 12/22/2019.

## Corresponding Author:

Mizanur Khondoker, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, United Kingdom.

Email: [m.khondoker@uea.ac.uk](mailto:m.khondoker@uea.ac.uk)

of people with dementia and declined longitudinally over 10 years, as opposed to healthy older adults. In a recent study by Giebel et al,<sup>14</sup> a larger number of IADLs was compared across mild, moderate, and severe dementia, although the study was not based on longitudinal data. As expected, individual activities such as preparing a hot meal and finance management were more impaired, the more advanced the dementia stage. This hierarchical decline of everyday activity performance is found to be associated with a decline in cognition,<sup>15</sup> with literature suggesting that deficits in general<sup>16</sup> and specific areas of cognition, such as executive functioning,<sup>17</sup> are linked with increased dependency levels. Considering different dependency levels across FTDs and AD dementia at baseline, it is important to investigate whether these variations are reflected in the longitudinal decline of everyday functioning abilities across syndromes.

Everyday activities probably deteriorate differently across dementia syndromes. Mioshi and Hodges<sup>18</sup> reported different levels of ADL decline between bvFTD, semantic dementia, and progressive nonfluent aphasia (PNFA) variants over 12 months. In particular, only patients with PNFA were reported to have a significant deterioration in total ADL and total IADL functioning over 12 months. In 2 recent studies similarly focusing on FTD syndromes, O'Connor et al<sup>2</sup> reported similar levels of everyday functioning decline between patients with svPPA and nvPPA over 5 years, while in a separate analysis, patients with bvFTD were found to show faster levels of IADL decline.<sup>19</sup> These studies provide some important first insights; however, to existing knowledge, no study to date has compared individual IADL functioning across bvFTD and AD over a prolonged period of time. It is important to highlight the significant burden that problems with everyday activities can place both on the person living with dementia<sup>20,21</sup> and on the caregiver.<sup>22,23</sup> In particular, the increased decline in symptomatology in bvFTD<sup>24</sup> can have a more severe impact on caregiver well-being than in other syndromes. Therefore, investigating these trajectories can help preparing both people with dementia and caregivers better in advance.

The objective of this study is to explore the trajectories of everyday functioning between bvFTD and AD dementia over time, by specifically focusing on individual daily activities and overall daily functioning. With only limited previous research on IADL functioning across differential diagnoses, and more specifically on trajectories of functioning decline over time, we aimed to investigate the levels of dependence at baseline and the performance trajectories over time. We hypothesized that people with bvFTD and ADD would experience different levels of decline over time, without specific hypotheses on which type would deteriorate faster. This knowledge can have important applications for clinical practice by potentially helping in planning effective care management for differential diagnoses, as the Alzheimer's Disease International Report (2011)<sup>25</sup> also outlines the value of early diagnosis for intervention planning.

## Method

### Participants


Data were used from the US National Alzheimer's Coordinating Center (NACC) data set, which collects longitudinal data from 34 Alzheimer's disease centers (ADCs) on demographic characteristics, dementia progression, and clinical diagnosis by clinicians from people with any cognitive status living in the community and long-term care institutions.<sup>26,27</sup> Written informed consents were obtained from participants at each ADC and approved by the institutional review board (IRB) of the ADC. Research using the NACC database was approved by the IRB of the University of Washington. Dementia diagnoses are provided by clinicians at each study center, and a diagnosis of AD dementia was based on recommendations from the National Institute on Aging–Alzheimer's Association workgroups,<sup>28</sup> The International Consensus Criteria for bvFTD<sup>4</sup> was used for a diagnosis of bvFTD.

The NACC data set was requested on November 2, 2012, and contained patient data from September 2005 to August 2012. For this study, 5000 patient cases were used, which had 36,456 individual visits in the extracted database. Each patient had several entries due to the follow-up data, so that each patient needs to be allocated an ID at first by the researchers. Of the 5000 coded cases, data from people with a diagnosis of bvFTD (N = 306) and AD dementia (N = 3043), all living in the community, were included in this analysis. The total eligible sample size was 3351, and the flow diagram for selection of the baseline sample is shown in Figure 1. With AD dementia being the most common dementia syndrome, more NACC cases had this diagnosis as opposed to bvFTD, so that the sample size of the bvFTD group was smaller. The NACC data set is representative of the dementia population at large and therefore contains a larger proportion of people with AD dementia. In order to increase the power of our analysis, we have chosen to analyze the 2 groups in observational (natural) setting without artificially downsizing the AD group, but with adequate statistical adjustment of potential confounding factors to make the 2 groups as balanced as possible.

### Measures

The Functional Activities Questionnaire (FAQ)<sup>29</sup> measured performance on 10 IADLs (bills, taxes, shopping, hobbies, using kitchen appliances, meal preparation, remembering events, paying attention, remembering appointments, traveling), which were scored from 0 to 3 (no problems to dependent). The total FAQ score is generated by adding up the individual activity scores, resulting in a maximum score of 30 (indicating full dependence).

General cognition was measured using the Mini-Mental State Examination (MMSE).<sup>30</sup> A total of 30 can be obtained on the MMSE, with higher scores indicating improved cognition. The MMSE is used as a tool to measure the severity of cognitive impairment. Cutoff points vary by study,<sup>31,32</sup> but typically scores of 26 or above are considered normal, 21 to



**Figure 1.** Schematic representation of the baseline sample selection. \*Cases were excluded because they did not have a dementia diagnosis of behavioral variant frontotemporal dementia or Alzheimer disease.

25 are suggested to indicate mild cognitive impairment, from 11 to 20 moderate, and scores from 0 to 10 are considered as severe cognitive impairment.<sup>32</sup>

Dementia severity was assessed using the Clinical Dementia Rating scale (CDR).<sup>33</sup> The CDR scores range from 0 to 3, with higher scores indicating increased severity. A score of “0” suggests no change in everyday living abilities, patients with very mild to mild dementia usually score “0.5” or “1,” respectively. A score of “2” or “3” is indicative of moderate and severe dementia, respectively.

Information on sociodemographics was collected at the first study visit and included data on age, gender, education, ethnicity, marital status, and living situation. The NACC data set does not collect data on age at diagnosis, but only at NACC visit.

## Data Analysis

Data were analyzed using IBM SPSS version 25. Descriptive analysis of demographic characteristics was performed using summary statistics such as mean, standard deviation, and frequency distributions. Continuous measures at baseline were compared between bvFTD and AD using independent samples *t* tests, and categorical measures were compared using  $\chi^2$  tests. Performance measure on each IADL at baseline was analyzed individually for each dementia syndrome and compared using independent samples *t* tests.

The longitudinal (repeated) performance measures of each IADL across dementia syndromes were analyzed using linear mixed-effect models. The linear mixed-effects models enabled comparing the differences in overall mean of performance scores across time points as well as the differences in trajectories over time between the dementia syndromes. Fixed effects in the models included diagnosis (bvFTD, AD dementia), time (the visit number with a maximum of 7 visits), and the interaction between diagnosis and time. We have used visit number as a proxy for the time variable. As can be expected

in an observational study, successive visits were not equally spaced, but visits were on average 1 year apart. The models included random intercepts for subject IDs to account for any correlation between the repeated measures within patients. One model was built for each individual IADL and for the total of all IADLs (FAQ<sub>Total</sub>) comparing performance measure for bvFTD and AD dementia. First, a linear mixed model as described above was built for the FAQ<sub>Total</sub> as the outcome measure. The same approach was used to analyze each of the individual 10 IADLs subsequently. The independent variables were diagnosis (categorical), time (continuous), and a set of potential confounders (patient age, patient gender, patient ethnicity, and years of education). In all models, AD dementia syndrome was used as the reference category for the diagnosis variable. As is the case for most longitudinal studies, there were fewer people in later visits (Table 1) due to dropouts. To minimize any potential bias due to differential dropout rates between the groups, we identified baseline variables that were associated with the dropout (eg, ethnicity) and included within the list of covariates in linear mixed model analyses.

## Results

### Demographics

Table 2 presents the demographic characteristics across dementia syndromes at baseline. People with bvFTD were younger (bvFTD mean age = 63 years, AD mean age = 75 years, independent sample *t* test *P* value <.001) and slightly more educated (bvFTD mean years of education = 15, AD mean years of education = 14, *P* < .05). The bvFTD group had on average higher severity levels (mean = 6.5) based on the CDR ratings than people with AD dementia (mean = 4.2, *P* < .001). The  $\chi^2$  tests showed significant differences across ethnicity,  $\chi^2(1) = 30.5$ , *P* < .001, gender,  $\chi^2(1) = 40.5$ , *P* < .001, and marital status,  $\chi^2(1) = 48.39$ , *P* < .001, with a larger proportion of people with bvFTD being male (64.7%; AD dementia =

**Table 1.** Number of People With Data at Different Assessment Visits Across Dementia Subtypes.

Visit Number	bvFTD	AD
1	306	3045
2	168	2058
3	81	1370
4	46	893
5	26	512
6	12	225
7	0	59

Abbreviations: AD, Alzheimer disease; bvFTD, behavioral variant frontotemporal dementia.

**Table 2.** Demographic Characteristics Across Dementia Subtypes.

	bvFTD, n = 306	AD, n = 3045
PwD age, mean (SD)	63.29 (10.05)	75.46 (9.17)
Education, mean (SD)	14.82 (3.25)	14.36 (3.79)
PwD gender, n (%)		
Female	108 (35.3)	1655 (54.4)
Male	198 (64.7)	1390 (45.6)
Ethnicity, n (%)		
White	281 (93.7)	2455 (80.8)
Non-white	19 (6.3)	583 (19.2)
Marital status, n (%)		
Married/living as married	264 (86.3)	2038 (68.7)
Widowed/divorced/separated/other	42 (13.7)	1007 (31.3)
CDR global, n (%)		
0	8 (2.6)	280 (9.2)
0.5	84 (27.5)	1487 (48.8)
1	133 (43.5)	921 (30.2)
2	59 (19.3)	273 (9.0)
3	22 (7.2)	84 (2.8)
CDR sum	6.49 (4.28)	4.18 (3.92)
MMSE (min = 0, max = 30)	22.72 (6.30)	23.07 (6.09)

Abbreviations: AD, Alzheimer disease; bvFTD, behavioral variant frontotemporal dementia; CDR, Cognitive Deterioration Rating; MMSE, Mini-Mental State Examination; PwD, person with dementia.

**Table 3.** Everyday Functional Variations Between Subtypes at Baseline.<sup>a</sup>

	bvFTD, n = 306	AD, n = 3045	Independent With 95% CI	t Tests
Finance management	2.2 (1.1)	1.4 (1.3)	t = 10.65 [0.61-0.89]	<.001
Assembling tax records, business affairs/papers	2.3 (1.0)	1.5 (1.3)	t = 12.09 [0.68-0.94]	<.001
Shopping	1.7 (1.1)	1.1 (1.2)	t = 8.98 [0.50-0.78]	<.001
Hobby	1.5 (1.2)	0.8 (1.1)	t = 9.63 [0.56-0.84]	<.001
Using kitchen appliances	1.1 (1.2)	0.6 (1.0)	t = 7.34 [0.40-0.69]	<.001
Preparing meal	1.7 (1.2)	1.0 (1.2)	t = 8.81 [0.52-0.82]	<.001
Keeping track of current events	1.4 (1.1)	1.0 (1.1)	t = 6.97 [0.34-0.60]	<.001
Paying attention	1.3 (1.0)	0.7 (1.0)	t = 9.1 [0.44-0.68]	<.001
Remembering appointments	1.8 (1.1)	1.4 (1.1)	t = 5.58 [0.24-0.50]	<.001
Traveling	1.9 (1.2)	1.3 (1.3)	t = 7.64 [0.43-0.72]	<.001
Total	20.3 (10.4)	15.5 (12.2)	t = 7.53 [3.57-6.09]	<.001

Abbreviations: AD, Alzheimer disease; bvFTD, behavioral variant frontotemporal dementia; CI, confidence interval; SD, standard deviation.

<sup>a</sup>Data are in mean (SD), ranging from 0 (independent) to 3 (dependent).

45.6%), white (bvFTD = 93.7%; AD dementia = 80.8%), and married (bvFTD = 86.3%; AD dementia = 68.7%).

Table 2 also shows the outcome measures on tests of cognition. Dementia severity as measured with the MMSE was not found to vary between people with AD dementia and bvFTD.

Table 1 shows the number of people with assessment data at different visits for each patient group. Participants had a maximum of 7 visits, with patients with bvFTD having assessment data up to the sixth visit. As is the case for most longitudinal studies, there are less people with assessment data at higher visits.


### Baseline Everyday Functioning Profiles by Syndrome

Table 3 shows the performance measures on the 10 IADLs across AD dementia and bvFTD at baseline. Managing bills (AD dementia = 1.4 [1.3]; bvFTD = 2.2 [1.1]) and assembling tax records (AD dementia = 2.3 [1.0]; bvFTD = 1.5 [1.3]) were the most impaired IADLs across both syndromes. Using kitchen appliances (AD dementia = 1.1 [1.2]; bvFTD = 0.6 [1.0]) was the least impaired across AD dementia and bvFTD. Independent samples *t* tests showed that people with bvFTD experienced greater impairments in all 10 IADLs compared to patients with AD dementia.

Figure 2 shows the proportion of people with bvFTD and AD dementia who were impaired on each IADL at baseline. A larger proportion of patients with bvFTD were impaired on all activities compared to those with AD dementia. Comparing the proportion of people who were impaired (Figure 2) with the average severity rating (Table 3) highlights that remembering appointments was impaired in a larger number of people with AD dementia than deficits with bills and taxes.

### Trajectories of Everyday Function Over Time

Longitudinal FAQ<sub>Total</sub> scores as well as scores on each individual IADL were analyzed using linear mixed-effect models across the 4 syndromes. Table 4 shows the results of the mixed



**Figure 2.** Everyday functional profiles of different dementia subtypes at baseline. Percentage of patients impaired on an activity within subtype diagnosis. Impairment includes a score between 1 and 3 on the Functional Activities Questionnaire (FAQ) item. AD indicates Alzheimer disease; bvFTD, behavioral variant frontotemporal dementia.

models considering  $FAQ_{Total}$  and the individual 10 IADLs. All mixed models controlled for the effects of age, gender, ethnicity, and education, to account for the differences at baseline.

Across all activities and  $FAQ_{Total}$ , patients with bvFTD showed significantly worse performance than those with AD dementia (*bills* coefficient = 0.82,  $P < .001$ ; *taxes* = 0.86,  $P < .001$ ; *shopping* = 0.78,  $P < .001$ ; *hobbies* = 0.69,  $P < .001$ ; *kitchen appliances* = 0.58,  $P < .001$ ; *meal preparation* = 0.80,  $P < .001$ ; *events* = 0.58,  $P < .001$ ; *paying attention* = 0.60,  $P < .001$ ; *remembering dates* = 0.43,  $P < .001$ ; *travel* = 0.66,  $P < .001$ ,  $FAQ_{Total}$  = 5.57,  $P < 0.001$ ).

The regression coefficients of time (visits), which represent the gradients or slopes of the IADL trajectories for the reference (AD) group, were positive for the total as well as each individual IADL, indicating that overall performance deteriorated over time. The rates of increase in impairment (slopes) were statistically significant for the total as well as for each individual IADL (*bills* = 0.17,  $P < .001$ ; *taxes* = 0.16,  $P < .001$ ; *shopping* = 0.19,  $P < .001$ ; *hobbies* = 0.17,  $P < .001$ ; *kitchen appliances* = 0.18,  $P < .001$ ; *meal preparation* = 0.19,  $P < .001$ ; *events* = 0.17,  $P < .001$ ; *paying attention* = 0.16,  $P < .001$ ; *remembering appointments* = 0.17,  $P < .001$ ; *travel* = 0.19,  $P < .001$ ;  $FAQ_{Total}$  = 1.47,  $P < .001$ ).

We compared the IADL trajectory slopes between the dementia syndromes by including the interaction (cross-product) term between diagnosis and time (visits). The coefficients of the interaction terms (displayed in Table 4) represent the difference in slopes of the IADL trajectories between bvFTD and AD dementia (the reference group). These results showed that performance on IADLs for patients with bvFTD declined at significantly faster rates than that of patients with AD dementia for *using the stove* (0.08,  $P < .01$ ) and *travel* (0.06,  $P < .05$ ). All other IADLs including the overall measure ( $FAQ_{Total}$ ) declined similarly across AD dementia and bvFTD.

We have also conducted a subgroup analysis using linear mixed model for the overall functional measure ( $FAQ_{Total}$ ) by splitting the sample into 2 groups by disease severity ( $CDR \leq 1$

vs  $CDR > 1$ ). The results (Supplemental Table A1) show that among the less severe patients ( $CDR \leq 1$ ), bvFTD group demonstrates poorer functional outcomes at baseline (coefficient = 4.22,  $P$  value  $< .001$ ) compared to the patients with AD. Among the more severe patients ( $CDR > 1$ ), bvFTD group demonstrates slightly better (coefficient =  $-0.14$ , but not statistically significant) functional outcomes than the patients with AD. However, in terms of the rate of change of longitudinal trajectory of overall everyday functioning profile, the bvFTD group did not differ significantly from the patients with AD within either of the severity categories, which is in agreement with the main analysis ( $CDR \leq 1$ : interaction coefficient = 0.05,  $P$  value = .91, 95% confidence interval [CI],  $-0.84$  to 0.94;  $CDR > 1$ : interaction coefficient =  $-0.35$ ,  $P$  value = .36, 95% CI,  $-1.09$  to 0.40; see Supplemental Table A1). In summary, it appears that patients with bvFTD demonstrate poorer functional outcomes, particularly in earlier stages of the disease with similar rates of change over time to AD. This is an interesting and important finding that provides support against the speculation that effects may have been driven by patients with bvFTD simply being further along in their disease stage.

Figure 3 shows the overall ( $FAQ_{Total}$ ) IADL trajectories over time (visit) for each dementia syndrome based on the linear mixed model analysis. Compared to AD dementia, people with bvFTD showed a similar rate of increase in impairment across the 7 visits, where data available, but starting at a higher initial level of impairment at the baseline visit.

## Discussion

This study adds novel findings based on in-depth everyday functioning profiles and their longitudinal trajectories between bvFTD and AD dementia. Previous research primarily focused on global performances,<sup>8,16,34</sup> or only on some activities,<sup>13</sup> while some research did not compare syndromes altogether.<sup>13</sup> With everyday functioning deficits linked to higher care costs and increased levels of carer burden,<sup>35</sup> this study may help identify more targeted care management for everyday functioning for AD dementia and bvFTD.

Corroborating previous evidence,<sup>9</sup> patients with bvFTD were found to be significantly more impaired than those with AD dementia at baseline. This corroborates previous findings by Mioshi and colleagues,<sup>8</sup> stating that global IADL functioning is impaired to a greater extent in bvFTD than in AD dementia, while adding further insights by showcasing the detailed levels of impairments for individual activities in the present study. Findings showed how patients with bvFTD were significantly more impaired on individual tasks such as finance management and engaging in hobbies compared to people with AD dementia. One potential reason for these variations in functional profiles both at baseline and in their rates of decline could be different rates and areas of cognition affected in each syndrome. Cognition has been shown to be one of the primary contributors to functional dependence in dementia<sup>9,36</sup> and declines alongside IADL functioning.<sup>15</sup> Although there are other factors that can contribute to dependence, such as

**Table 4.** Mixed-Effect Models for the Total FAQ and Individual IADLs as Outcomes.<sup>a</sup>


IADL	Parameter of the Model	Estimate (SE)	P	95% CI
Bills	Intercept	1.51 (0.21)	<.001	(1.11 to 1.91)
	bvFTD	0.82 (0.10)	<.001	(0.63 to 1.01)
	Visits	0.17 (0.01)	<.001	(0.16 to 0.19)
	bvFTD × visits	−0.001 (0.03)	.974	(−0.06 to 0.06)
Taxes	Intercept	1.73 (0.21)	<.001	(1.32 to 2.14)
	bvFTD	0.86 (0.10)	<.001	(0.67 to 1.05)
	Visits	0.16 (0.01)	<.001	(0.14 to 0.17)
	bvFTD × visits	−0.01 (0.03)	.650	(−0.07 to 0.04)
Shopping	Intercept	0.51 (0.19)	.006	(0.15 to 0.88)
	bvFTD	0.78 (0.09)	<.001	(0.61 to 0.96)
	Visits	0.19 (0.01)	<.001	(0.18 to 0.20)
	bvFTD × visits	0.04 (0.03)	.129	(−0.01 to 0.10)
Hobbies	Intercept	1.16 (0.18)	<.001	(0.81 to 1.51)
	bvFTD	0.69 (0.09)	<.001	(0.52 to 0.87)
	Visits	0.17 (0.01)	<.001	(0.15 to 0.18)
	bvFTD × visits	0.05 (0.03)	.100	(−0.01 to 0.11)
Using the stove	Intercept	0.53 (0.17)	.002	(0.20 to 0.86)
	bvFTD	0.58 (0.08)	.001	(0.42 to 0.75)
	Visits	0.18 (0.01)	<.000	(0.17 to 0.19)
	bvFTD × visits	0.08 (0.03)	.006	(0.02 to 0.13)
Preparing a meal	Intercept	0.77 (0.20)	<.001	(0.38 to 1.16)
	bvFTD	0.80 (0.10)	<.001	(0.62 to 0.99)
	Visits	0.19 (0.01)	<.001	(0.17 to 0.20)
	bvFTD × visits	0.04 (0.03)	.172	(−0.02 to 0.10)
Current events	Intercept	0.94 (0.17)	<.001	(0.60 to 1.28)
	bvFTD	0.58 (0.08)	<.001	(0.41 to 0.74)
	Visits	0.17 (0.01)	<.001	(0.16 to 0.19)
	bvFTD × visits	0.01 (0.03)	.640	(−0.04 to 0.07)
Paying attention	Intercept	0.71 (0.15)	<.001	(0.40 to 1.01)
	bvFTD	0.60 (0.08)	<.001	(0.45 to 0.75)
	Visits	0.16 (0.01)	<.001	(0.15 to 0.18)
	bvFTD × visits	0.001 (0.03)	.971	(−0.05 to 0.05)
Remembering appointments	Intercept	1.35 (0.17)	<.001	(1.01 to 1.69)
	bvFTD	0.43 (0.08)	<.001	(0.27 to 0.59)
	Visits	0.17 (0.01)	<.001	(0.15 to 0.18)
	bvFTD × visits	0.03 (0.03)	.263	(−0.02 to 0.08)
Travel	Intercept	0.92 (0.19)	<.001	(0.54 to 1.30)
	bvFTD	0.66 (0.09)	<.001	(0.48 to 0.84)
	Visits	0.19 (0.01)	<.001	(0.18 to 0.21)
	bvFTD × visits	0.06 (0.03)	.043	(0.002 to 0.12)
FAQ <sub>Total</sub>	Intercept	15.63 (1.82)	<.001	(12.07 to 19.20)
	bvFTD	5.57 (0.89)	<.001	(3.83 to 7.32)
	Visits	1.47 (0.07)	<.001	(1.32 to 1.61)
	bvFTD × visits	0.14 (0.30)	.643	(−0.46 to 0.74)

Abbreviations: AD, Alzheimer disease; bvFTD, behavioral-variant frontotemporal dementia; CI, confidence interval; FAQ, Functional Activities Questionnaire; IADL, instrumental activities of daily living; SE, standard error.

<sup>a</sup>Alzheimer disease diagnosis is the reference category. Coefficient of visits represents the slope for the reference category (AD subgroup). The interaction between diagnosis and visits represents the difference in slopes between the respective group and the reference group (AD). All models have been adjusted for the baseline covariates ethnicity, gender, age, and education.

physical limitations, depression, and environmental factors,<sup>37,38</sup> cognitive profiles and behavioral symptomatology differ between AD dementia and bvFTD.<sup>39-41</sup> Therefore, it is likely that these variations in cognitive profiles and behavioral changes throughout the dementia course are primary underlying factors as to the different functional profiles in those dementia syndromes. Executive functioning has been particularly linked with IADL performance,<sup>42</sup> specifically with

finance management tasks,<sup>43</sup> and is shown to deteriorate early on in the course of dementia. Comparing the longitudinal trajectory of executive dysfunction across bvFTD and AD dementia, only disinhibition is shown to distinguish both syndromes, although most other executive functions deteriorate relatively similarly.<sup>41</sup> Therefore, executive function may only partially explain differences in deterioration for *using the stove* and *travel* in this study. However, it may be worthwhile to note that the



**Figure 3.** Predicted overall IADL ( $FAQ_{Total}$ ) trajectories for each dementia subtype based on the linear mixed model analysis. The horizontal axis (visits) refers to the time when functional performance scores ( $FAQ_{Total}$ ) were measured.

behavioral dysregulation, stereotyped behaviors (eg, rigidity), and apathy, which are core distinguishing features of bvFTD, are arguably the most functionally impairing (to families) but not captured on neuropsychological testing. These features are likely to be contributing to their early functional impairment. Future research ought to explore the precise relationship of individual types of cognition, including executive function, prospective memory, and attention, as well as the contributions of behavioral symptoms, such as apathy, to the successful performance of everyday activities. Considering the paucity of literature on these relationships,<sup>44,45</sup> this study further showcases the relevance and value of improving this evidence base.

Patients with bvFTD showed a faster decline in functioning only for using the stove and travel. Variations in these 2 selected activities may be the result of different cognitive or neural correlates compared to other daily activities, which may be subject to greater or faster decline in bvFTD than in AD dementia. Literature on the cognitive and neural correlates of individual IADLs is still in its infancy,<sup>17,46-48</sup> and more research needs to be conducted to obtain a clearer picture of these potential underlying causes of faster decline in specific IADLs in bvFTD, as opposed to AD dementia. Previous research has shown that patients with bvFTD showed a faster decline than patients with svPPA in total ADL function over a period of 3 years,<sup>19</sup> whereas no research to date had emerged comparing the speed of decline between bvFTD and AD dementia. When breaking the activities down, it was basic ADL function that particularly showed the greater rate of decline, as opposed to IADL function.<sup>19</sup> It is important to consider that the longitudinal decline in this study was based on visit number as a proxy for the time variable. The successive visits were not equally spaced, which could have had an effect on the level of deterioration between visits. These variations in time space between visits were, however, present for both subgroups, so this should not have affected the comparison of decline rates between the subgroups.

Findings from this study can have several implications for both clinical practice and everyday care management of dementia. This study adds novel insights into the variations in everyday functioning profiles between AD dementia and bvFTD, which may be helpful in contributing to effective care management planning by tailoring care to the individual functional needs of different syndromes. For example, the knowledge that the ability to use kitchen appliances deteriorates faster in patients with bvFTD compared to those with AD dementia might suggest that care management needs to accommodate for these deficits and plan ahead. This is particularly important for those people with dementia who are being supported by a family carer. Family carers are vital in supporting their relative with dementia with daily activities and provide a large proportion of care in the home environment.<sup>49</sup> Particularly, caregiver stress is related to increased symptomatology of the person they are caring for,<sup>50</sup> suggesting that care planning should not only focus in the person with dementia but also on their family. Therefore, it is important to distinguish between different syndromes but also to investigate and understand the decline for individual IADLs.

There are several limitations and strengths to this study. An important unknown is how the diagnoses of bvFTD and AD dementia are differentially delayed. It is quite possible that bvFTD diagnoses are more difficult and thus patients are more impaired when they are seen in a research center compared to AD dementia. We were unable to directly control for possible effects of length of disease on the comparability of the trajectories between the 2 groups due to lack of such information in the data set. We have, however, adjusted all our linear mixed model analyses for participants' age, which we believe would have mitigated the potential effects of the length of disease to some extent. To justify this further, it may be noted that the average age of diagnosis of FTD is about 60, which is a full 10 years before the average patient with AD is diagnosed (Fast Facts About Frontotemporal Degeneration, 2011).<sup>51</sup> This difference in average age at diagnosis is similar to the difference in average age of the participants between the bvFTD and AD groups in our study sample (patients with bvFTD are on average 12 years younger; see Table 1). The adjustment for participants' age should therefore make the 2 groups more balanced (comparable) in terms of the age at diagnosis as well. Although this study benefits from a very large national sample, by data having been collected from 34 AD research centers, the AD dementia group was substantially larger than the bvFTD group. Considering the higher incidence rate of AD dementia compared to bvFTD, however,<sup>52</sup> it is expected to have smaller numbers in the bvFTD subgroup. With the aim of maximizing the power of this study, all patients with AD dementia were included in the analysis. The preselection of the first 5000 cases only of the existing Uniform Data Set could represent a limitation, in that it may be considered as a selection bias of the data. However, as elaborated above, the first 5000 cases were selected as they were deemed sufficiently large to ensure the statistical comparison of the dementia subgroups. A total of 27 772 individual entries of patient visits remained (both



baseline and follow-up visits), which were not coded and allocated an individual patient ID. One further limitation could be the informant-reported nature of the everyday functioning abilities. These may provide potential bias in that carers have been shown to differ from directly observed measures of everyday functioning.<sup>53</sup> Indirect reports, as opposed to directly observed performances of ADL functioning, are, however, frequently employed in ADL research,<sup>23,54,55</sup> and without directly observed ADL data collected as part of the NACC Uniform Data Set, the fact that indirect reports of functioning may only represent a minor limitation.

## Conclusions

Findings from this study have implications for the effective care management of everyday functioning across different dementia syndromes. People with bvFTD show faster rates of decline for *using the stove* and *travel* compared to people with AD dementia. Care management can take these variations into account at the point of diagnosis and address those activities that are found to be more or earlier impaired in certain syndromes compared to others. With IADL and ADL dependence constituting one of the major cost factors in dementia,<sup>56</sup> and being one of the primary reasons for admission into a long-term care institution, effectively managing increased dependence for each syndrome can potentially have an effect on long-term care admissions. Future research should explore how these variations in everyday functioning can indeed be integrated in interventions and clinical practice.

## Authors' Note

E.M. conceived the idea and both E.M. and C.G. codesigned the study. M.K. designed the statistical analysis plan; C.G. and M.K. conducted the analyses. C.G. drafted the manuscript. D.K., E.M., and M.K. provided critical comments on important intellectual contents. C.G. and M.K. revised the manuscript. All authors contributed in the interpretation of data for the work.

## Declaration of Conflicting Interests


The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Knopman serves on a Data Safety Monitoring Board for the DIAN study and previously had served on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the Alzheimer's Disease Cooperative Study; and receives research support from the NIH.

## Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The NACC database is funded by NIA/NIH grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD,

PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD). This project was partly funded by The National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC). E.M. is supported by the National Institute of Health Research (NIHR) Applied Research Collaboration East of England (ARC EoE) program. The views expressed are those of the authors and not necessarily those of the NIHR, NHS, or Department of Health and Social Care. Dr Knopman receives funding from NIH grants P50 AG16574.

## ORCID iD

Mizanur Khondoker  <https://orcid.org/0000-0002-1801-1635>

## Supplemental Material

Supplemental material for this article is available online.

## References

1. Liu-Seifert H, Siemers E, Sundell K, et al. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. *J Alzheimer's Dis.* 2015;43(3):949-955.
2. O'Connor CM, Clemson L, Flanagan E, et al. The relationship between behavioural changes, cognitive symptoms, and functional disability in primary progressive aphasia: a longitudinal study. *Dement Geriatr Cogn Disord.* 2016;42(3-4):215-226.
3. Giebel CM, Burns A, Challis D. Taking a positive spin: preserved initiative and performance of everyday activities across mild Alzheimer's, vascular and mixed dementia. *Int J Geriatr Psychiatry.* 2017;32(9):959-967.
4. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain.* 2011;134(9):2456-2477.
5. Devenney E, Vucic S, Hodges JR, Kiernan MC. Motor neuron disease-frontotemporal dementia: a clinical continuum. *Exp Rev Neurother.* 2015;15(5):509-522.
6. Hardy CJ, Buckley AH, Downey LE, et al. The language profile of behavioral variant frontotemporal dementia. *J Alzheimer's Dis.* 2016;50(2):359-371.
7. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. *Ann Neurol.* 2004;55(3):335-346.
8. Mioshi E, Kipps C, Dawson K, Mitchell J, Graham A, Hodges J. Activities of daily living in frontotemporal dementia and Alzheimer disease. *Neurology.* 2007;68(24):2077-2084.
9. Lima-Silva TB, Bahia VS, Carvalho VA, et al. Direct and indirect assessments of activities of daily living in behavioral variant



- frontotemporal dementia and Alzheimer disease. *J Geriatr Psychiatry Neurol.* 2015;28(1):19-26.
10. Wicklund AH, Johnson N, Rademaker A, Weitner BB, Weintraub S. Profiles of decline in activities of daily living in non-Alzheimer dementia. *Alzheimer Dis Assoc Disord.* 2007;21(1):8-13.
  11. Reisberg B, Ferris SH, Anand R, et al. Functional staging of dementia of the Alzheimer type. *Ann New York Acad Sci.* 1984; 435(1):481-483.
  12. Giebel CM, Sutcliffe C, Challis D. Activities of daily living and quality of life across different stages of dementia: a UK study. *Aging Mental Health.* 2015;19(1):63-71.
  13. Peres K, Helmer C, Amieva H, et al. Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study. *J Am Geriatr Soc.* 2008;56(1):37-44.
  14. Giebel CM, Sutcliffe C, Challis D. Hierarchical decline of the initiative and performance of complex activities of daily living in dementia. *J Geriatr Psychiatry Neurol.* 2017;30(2):96-103.
  15. Handels RL, Xu W, Rizzuto D, et al. Natural progression model of cognition and physical functioning among people with mild cognitive impairment and Alzheimer's disease. *J Alzheimer's Dis.* 2013;37(2):357-365.
  16. Wattmo C, Minthon L, Wallin ÅK. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. *Alzheimer's Res Ther.* 2016;8(1):7.
  17. Razani J, Wong JT, Dafaeeboini N, et al. Predicting everyday functional abilities of dementia patients with the Mini-Mental State Examination. *J Geriatr Psychiatry Neurol.* 2009;22(1): 62-70.
  18. Mioshi E, Hodges J. Rate of change of functional abilities in frontotemporal dementia. *Dement Geriatr Cogn Disord.* 2009; 28(5):419.
  19. O'Connor CM, Clemson L, Hornberger M, et al. Longitudinal change in everyday function and behavioral symptoms in frontotemporal dementia. *Neurol: Clin Pract.* 2016;6(5):419-428.
  20. Miguel S, Alvira M, Farré M, Risco E, Cabrera E, Zabalegui A. Quality of life and associated factors in older people with dementia living in long-term institutional care and home care. *Eur Geriatr Med.* 2016;7(4):346-351.
  21. Giebel CM, Sutcliffe C. Initiating activities of daily living contributes to well-being in people with dementia and their carers. *Int J Geriatr Psychiatry.* 2018;33(1):e94-e102.
  22. Razani J, Corona R, Quilici J, et al. The effects of declining functional abilities in dementia patients and increases in psychological distress on caregiver burden over a one-year period. *Clin Gerontol.* 2014;37(3):235-252.
  23. Fauth EB, Femia EE, Zarit SH. Resistiveness to care during assistance with activities of daily living in non-institutionalized persons with dementia: associations with informal caregivers' stress and well-being. *Aging Mental Health.* 2016;20(9):888-898.
  24. Schubert S, Leyton CE, Hodges JR, Piguet O. Longitudinal memory profiles in behavioral-variant frontotemporal dementia and Alzheimer's disease. *J Alzheimer's Dis.* 2016;51(3):775-782.
  25. Prince M, Bryce R, Ferri C. World Alzheimer Report 2011: the benefits of early diagnosis and intervention. 2011.
  26. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. *Alzheimer Dis Assoc Disord.* 2006; 20(4):210-216.
  27. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. *Alzheimer Dis Assoc Disord.* 2007;21(3):249-258.
  28. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. *Alzheimer's Dement.* 2011;7(3):263-269.
  29. Pfeffer RI, Kurosaki T, Harrah C Jr, Chance J, Filos S. Measurement of functional activities in older adults in the community. *J Gerontol.* 1982;37(3):323-329.
  30. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975;12(3):189-198.
  31. Perneckzy R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A. Mapping scores onto stages: Mini-Mental State Examination and Clinical Dementia Rating. *Am J Geriatr Psychiatry.* 2006;14(2):139-144.
  32. Kennedy RE, Cutter GR, Wang G, Schneider LS. Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: how does Mini-Mental State Examination predict rate of change? *Alzheimer's Dement (N Y).* 2015;1(1):46-52.
  33. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology.* 1993;43(11):2412-2414.
  34. Suh GH, Ju YS, Yeon BK, Shah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. *Int J Geriatr Psychiatry.* 2004;19(9):817-824.
  35. Reed C, Belger M, Vellas B, et al. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease. *Int Psychogeriatr.* 2016;28(2):247-259.
  36. Vermeersch S, Gorus E, Cornelis E, De Vriendt P. An explorative study of the relationship between functional and cognitive decline in older persons with mild cognitive impairment and Alzheimer's disease. *Br J Occup Ther.* 2015;78(3):166-174.
  37. Knapskog AB, Barca ML, Engedal K. Prevalence of depression among memory clinic patients as measured by the Cornell Scale of Depression in Dementia. *Aging Mental Health.* 2014;18(5): 579-587.
  38. Stogmann E, Moser D, Klug S, et al. Activities of daily living and depressive symptoms in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer's disease. *J Alzheimer's Dis.* 2016;49(4):1043-1050.
  39. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. *Neurology.* 2011; 76(11):1006-1014.
  40. Leslie F, Foxe D, Daveson N, Flanagan E, Hodges J, Piguet O. FRONTIER Executive Screen: a brief executive battery to differentiate frontotemporal dementia and Alzheimer's disease. *J Neurol Neurosurg Psychiatry.* 2016;87(8):831-835.
  41. Ramanan S, Bertoux M, Flanagan E, et al. Longitudinal executive function and episodic memory profiles in behavioral-variant

- frontotemporal dementia and Alzheimer's disease. *J In Neuropsychol Soc.* 2017;23(1):34-43.
42. Moheb N, Mendez MF, Kremen SA, Teng E. Executive dysfunction and behavioral symptoms are associated with deficits in instrumental activities of daily living in frontotemporal dementia. *Dement Geriatr Cognit Disord.* 2017;43(1-2):89-99.
43. Giebel CM, Flanagan E, Sutcliffe C. Predictors of finance management in dementia: managing bills and taxes matters. *Int Psychogeriatr.* 2019;31(2):277-286.
44. Ramsden CM, Kinsella GJ, Ong B, Storey E. Performance of everyday actions in mild Alzheimer's disease. *Neuropsychology.* 2008;22(1):17.
45. Roy K, Pepin LC, Philiossaint M, et al. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum. *J Alzheimer's Dis.* 2014;42(1):291-300.
46. Knapp M, Prince M, Albanese E, et al. *Dementia UK: The Full Report.* 2007. London, England: Alzheimer's Society.
47. Melrose RJ, Ettenhofer ML, Harwood D, et al. Cerebral metabolism, cognition, and functional abilities in Alzheimer disease. *J Geriatr Psychiatry Neurol.* 2011;24(3):127-134.
48. Pirogovsky E, Martinez-Hannon M, Schiehser DM, et al. Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson's disease. *J Clin Exper Neuropsychol.* 2013;35(9):926-933.
49. Kasper JD, Freedman VA, Spillman BC, Wolff JL. The disproportionate impact of dementia on family and unpaid caregiving to older adults. *Health Aff.* 2015;34(10):1642-1649.
50. Sutcliffe C, Giebel C, Bleijlevens M, et al. Caring for a person with dementia on the margins of long-term care: a perspective on burden from 8 European countries. *J Am Med Direct Assoc.* 2017;18(11):967-973. e961.
51. Association for Frontotemporal Degeneration. Fast facts about frontotemporal degeneration. 2011. <https://www.theaftd.org/wp-content/uploads/2009/05/Fast-Facts-Final-11-12.pdf>. Accessed October 8, 2019.
52. Zanetti O, Geroldi C, Frisoni GB, Bianchetti A, Trabucchi M. Contrasting results between caregiver's report and direct assessment of activities of daily living in patients affected by mild and very mild dementia: the contribution of the caregiver's personal characteristics. *J Am Geriatr Soc.* 1999;47(2):196-202.
53. Delva F, Touraine C, Joly P, et al. ADL disability and death in dementia in a French population-based cohort: new insights with an illness-death model. *Alzheimer's Dement.* 2016;12(8):909-916.
54. Lin LP, Hsu SW, Hsia YC, Wu CL, Chu C, Lin JD. Association of early-onset dementia with activities of daily living (ADL) in middle-aged adults with intellectual disabilities: the caregiver's perspective. *Res Dev Disabil.* 2014;35(3):626-631.
55. Åkerborg Ö, Lang A, Wimo A, et al. Cost of dementia and its correlation with dependence. *J Aging Health.* 2016;28(8):1448-1464.
56. Gaugler JE, Yu F, Krichbaum K, Wyman JF. Predictors of nursing home admission for persons with dementia. *Med Care.* 2009;47(2):191-198.